SYRS News and Press, Syros Pharmaceuticals Inc. From 11/12/19

Presented New Clinical Data from Phase 2 Study of SY-1425 in RARA-Positive Newly Diagnosed Unfit AML Patients at ESH Conference Presented New Preclinical Data on SY-5609 at AACR-NCI-EORTC Conference On Track for Key 2020 Milestones, Including Potential Proof-of-Concept Data for...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel fetal hemoglobin repressor in an oral presentation at the 61 st American Society of Hematol...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide...

SY-5609 Shows Robust Anti-Tumor Activity in Lung, Breast and Ovarian Cancer Models Deeper and More Sustained Responses Associated with RB Pathway Alterations Preclinical Data Support Planned Clinical Trial Strategy for SY-5609; Phase 1 Initiation Expected Q1 2020 Syros Pharma...

Thinly traded micro cap Syros Pharmaceuticals ( SYRS -4.8% ) slips on average volume on the heels of update results from its ongoing 40-subject  Phase 2 clinical trial evaluating lead drug SY-1425, combined with chemo agent azacitidine, in newly diagnosed patients with relapsed/refra...

62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence Data Support RARA as the Optimal Predictive Biomarker for Patient Selection Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the ...

Investment thesis: Biotechnology investors work on the assumption that news surrounding assets in clinical development impact company valuation significantly. Our analysis suggests that focusing on earlier events, such as Phase 2 and 3 data release, represents a stronger short-term, cataly...

Thursday was a good day on Wall Street, as investors were pleased to see many high-profile companies in the U.S. report positive earnings results. Geopolitical concerns also worked in the stock market's favor, with the U.K. and the European Union apparently agreeing to a deal that would allow Br...

Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 Inhibitor Expects to Initiate Phase 1 Trial of SY-5609 in First Quarter of 2020 Management to Host Conference Call at 8:30 a.m. ET Today Syros...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference. Details are as follows: ...